C. Lorenz

发表

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma

Roman K. Thomas, G. Kéri, M. Peifer, 2017, Cell reports.

Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients

T. Wurdinger, E. Thunnissen, G. Hartmann, 2017, Clinical Cancer Research.

MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer

A. Letai, Roman K. Thomas, L. Byers, 2019, Nature Communications.

CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization

K. Shokat, Roman K. Thomas, M. Peifer, 2022, Molecular cancer therapeutics.

Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.

M. Sos, P. Nussbaumer, B. Klebl, 2022, Journal of medicinal chemistry.

In vitro model for resistance in oncogene-dependent tumors at the limit of radiological detectability

Roman K. Thomas, M. Peifer, M. Sos, 2019, bioRxiv.

MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

C. Schmitt, Roman K. Thomas, G. Hartmann, 2021, Nature Communications.

Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer

K. Shokat, Roman K. Thomas, M. Peifer, 2017 .

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors

K. Shokat, Roman K. Thomas, M. Peifer, 2017, Science Translational Medicine.

Molecular Heterogeneity and Evolution in Breast Cancer

Jennifer L. Caswell-Jin, C. Curtis, C. Lorenz, 2021 .